Funding Strategies For Life Science Companies

  • Tuesday, January 10th, 2012. 11am.

    Funding Strategies for Life Sciences Companies
    Over the past several years, the primary sources for life sciences funding have remained largely the same. However, our research indicates that the financial crisis has led to a shift in the popularity, focus and type of deals that are being done. Further, the bar has undoubtedly been raised for life sciences companies seeking funding because investors’ appetite for risk has decreased significantly.
    Many criteria can be used to evaluate financing options – all of which have pros and cons depending on the current position and future direction of your business.

    Join members of Grant Thornton’s Life sciences practice as we discuss:

    • The pros and cons of various funding sources
    • Venture capital trends and opportunities
    • New opportunities in government funding
    • Tips to developing the optimal financing strategy for your business


    Faculty

    Michael Buher Partner, Life Sciences Practice, Mid-Atlantic, Grant Thornton LLP

    Michael Buher is an Audit Partner with Grant Thornton with over twenty years of experience working in the life science, technology, consumer business, and manufacturing, industries. He has extensive experience serving growth-oriented privately-held clients as well as global strategic clients and public registrants.

    Mike serves on the national life sciences leadership team and is one of the Firm’s key leaders in the Mid-Atlantic technology practice. His current clients include such biotechnology companies as Osiris Therapeutics and Spherix Inc. Some of his other notable clients are US Silica, Carey International, and Airlines Reporting Corporation.

    Prior to joining Grant Thornton, Mike spent 15 years with Deloitte & Touche where he worked with a variety of companies in the technology and consumer business industries, including mult-national public registrants and private companies.

    Mike is also involved in several community activities. He currently serves on the executive committee of the Tech Council of Maryland and serves in a variety of roles in other community organizations such as the Boy Scouts of America and the Emmorton Recreation Council.

    Jeff Ostapeic Partner, Life Sciences Practice, Minneapolis, Grant Thornton LLP

    Jeff is an audit partner in the Minneapolis office of Grant Thornton. He has over 20 years of combined accounting experience in private industry and public practice. Jeff is the leader of the Minneapolis Life Science Industry team. Prior to joining the Firm, Jeff worked for a Big Four firm for more than 15 years. Jeff also worked for three years as a partner in another National CPA firm. During his tenure he gained considerable experience working with SEC registrants, multinational corporations, medium to large privately-held companies and international organizations. Jeff’s primary areas of expertise include accounting and auditing. Throughout his professional career, Jeff has provided sound advice and planning strategy for complex audit engagements.
    His SEC experience includes serving various public companies and participating in numerous public offerings. His primary responsibility in the audit practice is to manage the services provided to his clients.

    Tim Zingraf Partner, Life Sciences Practice, San Francisco, Grant Thornton LLP

    Tim is an audit partner for Grant Thornton’s Greater Bay Area offices. Tim also leads our Bay Area Technology Industry Practice and is a member of Grant Thornton’s National Life Sciences Industry Team. Tim has over 25 years of experience providing services to technology and life sciences companies, including over 15 years of experience in public accounting. Clients served range from development stage enterprises to a Fortune 15 pharmaceutical distribution company. His industry experience includes serving as Vice President and Chief Accounting Officer for a publicly-held provider of home infusion therapies. Tim is experienced with SEC filings, public offerings, start-up and growth company activities, and emerging accounting issues such as stock-based compensation and revenue recognition.